Barclays PLC Purchases 21,598 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT)

Barclays PLC raised its position in shares of Galectin Therapeutics Inc. (NASDAQ:GALT) by 309.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 28,587 shares of the company’s stock after acquiring an additional 21,598 shares during the period. Barclays PLC’s holdings in Galectin Therapeutics were worth $79,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the company. Soltis Investment Advisors LLC bought a new stake in Galectin Therapeutics in the 3rd quarter valued at $387,000. Sanctuary Advisors LLC bought a new stake in shares of Galectin Therapeutics in the second quarter valued at about $227,000. Bank of New York Mellon Corp bought a new stake in shares of Galectin Therapeutics in the second quarter valued at about $146,000. Kovitz Investment Group Partners LLC acquired a new stake in Galectin Therapeutics during the third quarter worth about $117,000. Finally, Squarepoint Ops LLC increased its stake in Galectin Therapeutics by 75.4% during the second quarter. Squarepoint Ops LLC now owns 84,074 shares of the company’s stock valued at $190,000 after acquiring an additional 36,139 shares during the period. 11.68% of the stock is currently owned by institutional investors.

Galectin Therapeutics Stock Down 0.8 %

NASDAQ:GALT opened at $1.22 on Friday. The firm has a market capitalization of $76.57 million, a PE ratio of -1.67 and a beta of 0.83. Galectin Therapeutics Inc. has a 12-month low of $0.73 and a 12-month high of $4.27. The firm has a 50-day moving average price of $1.75 and a 200 day moving average price of $2.27.

Analysts Set New Price Targets

GALT has been the topic of several recent research reports. StockNews.com lowered Galectin Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, December 30th. HC Wainwright reiterated a “neutral” rating on shares of Galectin Therapeutics in a research note on Friday, December 27th.

Insider Activity

In other news, CFO Jack W. Callicutt sold 40,000 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $0.89, for a total value of $35,600.00. Following the transaction, the chief financial officer now directly owns 7,614 shares of the company’s stock, valued at $6,776.46. The trade was a 84.01 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Joel Lewis sold 56,000 shares of the stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $0.89, for a total value of $49,840.00. Following the sale, the chief executive officer now owns 897,012 shares in the company, valued at approximately $798,340.68. This trade represents a 5.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 109,654 shares of company stock worth $97,456. Company insiders own 50.10% of the company’s stock.

Galectin Therapeutics Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.